| Prev Close: | 32.08 |
|---|---|
| Open: | 31.35 |
| Bid: | 25.20 x 200 |
| Ask: | 33.09 x 100 |
| 1y Target Est: | 38.35 |
| Beta: | 1.35 |
| Next Earnings Date: | 29-Jul-13 |
| Day's Range: | 31.26 - 32.48 |
|---|---|
| 52wk Range: | 21.26 - 40.87 |
| Volume: | 248,649 |
| Avg Vol (3m): | 459,724 |
| Market Cap: | 1.29B |
| P/E (ttm): | 8.87 |
| EPS (ttm): | 3.63 |
| Div & Yield: | N/A (N/A) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Alkermes Earnings Beat Estimates, But Outlook Unclearat Investor's Business Daily(Thu 6:25PM EDT)
- Alkermes posts 4Q profit as royalty payments riseAP(Thu 12:44PM EDT)
- Alkermes Earnings Seen Rising, But Sales Uncertainat Investor's Business Daily(Wed, May 22)
- Additional Patent for Acorda's AmpyraZacks(Wed, May 22)
- CORRECTING and REPLACING Acorda Therapeutics Announces Publication of New Data on Impact of Mobility Impairment Due to Multiple SclerosisBusiness Wire(Tue, May 21)
- InPlay: Acorda Therapeutics announces publication of new data on impact of mobility impairment due to multiple sclerosisBriefing.com(Tue, May 21)
- ACORDA THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Tue, May 21)
- 4 Healthcare Stock Stories Prescribed For Investorsat Wall St. Cheat Sheet(Mon, May 20)
- Acorda Therapeutics Announces Issuance of Additional U.S. Patent for AMPYRA® Covering a Range of Dosage StrengthsBusiness Wire(Mon, May 20)
- ACORDA THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Mon, May 20)
- ACORDA THERAPEUTICS INC FinancialsEDGAR Online Financials(Fri, May 17)
- Acorda Therapeutics’ Legal Department Recognized on Best Legal Departments List by Corporate Counsel MagazineBusiness Wire(Fri, May 17)
- Acorda Therapeutics to Present at the UBS Global Healthcare ConferenceBusiness Wire(Wed, May 15)
- ACORDA THERAPEUTICS INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 10)
- Acorda says data support initiation of current dalfampridine development programtheflyonthewall.com(Thu, May 9)
Press Releases
- CORRECTING and REPLACING Acorda Therapeutics Announces Publication of New Data on Impact of Mobility Impairment Due to Multiple SclerosisBusiness Wire(Tue, May 21)
- Acorda Therapeutics Announces Issuance of Additional U.S. Patent for AMPYRA® Covering a Range of Dosage StrengthsBusiness Wire(Mon, May 20)
- Acorda Therapeutics’ Legal Department Recognized on Best Legal Departments List by Corporate Counsel MagazineBusiness Wire(Fri, May 17)
Reports
- ACOR - Acorda Therapeutics Inc - Rated a Hold - Company Analysis and ASR Ranking...Alpha Street Research(May 24)
- ACOR: Due Diligence Review: Forensic Earnings and ValuationNew Constructs, LLC(May 23)
- ValuEngine Detailed Valuation Report for ACORValuEngine, Inc.(May 23)